InsidersTradesSigma
Follow the ZyVersa Therapeutics, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.4m. The latest transaction was reported on 20 December 2022 (Attribution). Among the most active insiders: Wolfe Peter. All data is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
ZyVersa Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for inflammatory and metabolic diseases. It aims to create therapies that target underlying disease mechanisms.